Pharmaceutical CDMO Market To Reach $235.5 Billion By 2030

Pharmaceutical CDMO Market Growth & Trends

The global pharmaceutical CDMO market size is anticipated to reach USD 235.5 billion by 2030 and it is projected to grow at a CAGR of 7.2% from 2024 to 2030, according to a new report by Grand View Research, Inc. A growing consumption of biopharmaceuticals, rising demand for advanced therapeutics, demand for orphan drug discovery, upsurge number of clinical trials and increasing demand for one-stop-shop CDMOS are anticipated to influence the global market positively.

In addition, increasing pharmaceutical R&D investments can drive the market growth. As pharmaceutical companies invest more in R&D, they may seek external expertise and resources to accelerate drug development processes. CDMOs provide specialized services in drug development, manufacturing, and testing, making them valuable partners for pharmaceutical companies looking to outsource certain aspects of their R&D activities. Several players are investing in R&D activities of pharmaceuticals. For instance, in 2022, F. Hoffmann La Roche increased its R&D spending to USD 14.7 billion from USD 13.3 billion in the previous year. Another major player in pharmaceutical R&D expenditures for the same period was Merck & Co., allocating USD 13.5 billion to R&D. Janssen, the pharmaceutical arm of Johnson & Johnson, followed with an investment of USD 11.6 billion, slightly lower than the previous year's USD 11.9 billion.

Besides, increasing outsourcing services by pharmaceutical companies in the pharmaceutical industry has profoundly impacted the market. The trend of outsourcing activities in pharmaceutical domain is rising as companies find value in acquiring additional competencies essential for successful drug development & commercialization. Besides providing extended expertise & assisting in improved cash flow management, outsourcing brings significant manufacturing advantages, including reducing investment risks.

Notably, in the context of early-stage technologies and products, establishing expensive in-house capabilities entails substantial risks across product development phases. At the same time, outsourcing serves as a risk-averse alternative. In addition, having a limited understanding of the required scale for current & future product offerings or market penetration poses significant hurdles in designing and scaling manufacturing for in-house production. Consequently, the preference for outsourcing has grown as an effective strategy until market demand for products becomes well-established & understood.

Furthermore, the global distribution of clinical trials is expected to boost market growth. Clinical trials are executed globally, and their geographical distribution is shaped by diverse factors such as disease prevalence, regulatory conditions, population demographics, healthcare infrastructure, and cost considerations. As of February 2024, there is a discernible trend towards a more globalized approach to clinical trials. Over half of all registered studies are conducted outside the U.S. Meanwhile, over 35% of trials are exclusively conducted within the U.S. This emphasizes increasing international collaboration in collective pursuit of medical advancement.

 Request a free sample copy or view report summary: Pharmaceutical CDMO Market Report

Pharmaceutical CDMO Market Report Highlights

• Based on product, the active pharmaceutical ingredient (API) segment led the market with the largest revenue share of 81.20% in 2023. The segment growth is driven by competitive drug development and growing demand for end-to-end Contract Development & Manufacturing Organization (CDMO) services. In addition, advancements in API manufacturing, growth of the biopharmaceutical sector, and increasing geriatric population are some of the key factors propelling segment growth

• Based on the workflow, the commercial segment held the largest market share in 2023 attributed to robust demand for pharmaceutical products, such as biosimilar medications, generic medications, and regenerative therapies. This is where commercial CDMOs may help by providing knowledge, saving time, and being cost-effective

• Based on application, the oncology segment dominated the market with the largest revenue share of 21.82% in 2023. The segment is driven by an increasing number of cancer cases globally. In addition, increasing pharmaceutical R&D investments, patent expirations, and demand for oncology drugs & biologic innovations are the factors driving the oncology market

• Asia Pacific dominated the market with the revenue share of 37.64% in 2023. The presence of various factors, such as improved social insurance schemes & constantly improving economic conditions, which allow patients to pay out-of-pocket pharmaceutical costs is expected to drive market significantly

Pharmaceutical CDMO Market Segmentation

Grand View Research has segmented the pharmaceutical CDMO market report based on product, workflow, application, end-use, and region:

Pharmaceutical CDMO Product Outlook (Revenue, USD Million, 2018 - 2030)

• API

  • Type

    • Traditional Active Pharmaceutical Ingredient (Traditional API)

    • Highly Potent Active Pharmaceutical Ingredient (HP-API)

    • Antibody Drug Conjugate (ADC)

    • Others

  • Synthesis

    • Synthetic

      • Solid

      • Liquid

    • Biotech

  • Drug

    • Innovative

    • Generics

  • Manufacturing

    • Continuous manufacturing

    • Batch manufacturing

• Drug Product

  • Oral solid dose

  • Semi-solid dose

  • Liquid dose

  • Others

Pharmaceutical CDMO Workflow Outlook (Revenue, USD Million, 2018 - 2030)

• Clinical

• Commercial

Pharmaceutical CDMO Application Outlook (Revenue, USD Million, 2018 - 2030)

• Oncology

  • Small Molecules

  • Biologics

• Infectious Diseases

• Neurological Disorders

• Cardiovascular Disease

• Metabolic Disorders

• Autoimmune Diseases

• Respiratory Diseases

• Ophthalmology

• Gastrointestinal Disorders

• Hormonal Disorders

• Hematological Disorders

• Others

Pharmaceutical CDMO End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Small Pharmaceutical Companies

• Medium Pharmaceutical Companies

• Large Pharmaceutical Companies

Pharmaceutical CDMO Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Mexico

  • Argentina

• Middle East and Africa (MEA)

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Pharmaceutical CDMO Market

• Lonza

• Thermo Fisher Scientific, Inc.

• Recipharm AB

• Laboratory Corporation of America Holdings (LabCorp)

• Catalent, Inc.

• WuXi AppTec, Inc.

• Samsung Biologics

• Piramal Pharma Solutions

• Siegfried Holding AG

• CordenPharma International

• Cambrex Corporation

• Bushu Pharmaceuticals Ltd.

• Nipro Corporation